Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2009

View Archived Issues

Oral Alequel shows promise in a phase II trial for the treatment of Crohn's disease

Sarcoma treatment snapshots from ASCO

Forest reports results from FOCUS I and II phase III studies of ceftaroline in CABP

Takeda presents novel MEK/ERK inhibitors as oncolytics

Interim data from phase II trials support the potential of SB-509 in diabetic peripheral neuropathy

Diamyd vaccine proven safe and immunogenic in children and adolescents with type 1 diabetes

Improved lean body mass by MK-0773 not associated with hypertrophic prostatic activity

Positive results seen with recombinant measles vaccine in phase I study

Novartis quadrivalent meningococcal vaccine safe and immunogenic in infant population

Merck & Co. and DNDi enter master agreement for neglected tropical diseases

USAN approved generic name of Clinical Data's vilazodone hydrochloride for depression

Biovitrum transfers preclinical GPR-119 and SCD-1 diabetes projects to iNovacia

Biogen Idec enrolls first patient in phase III ADVANCE clinical trial of BIIB-017 in RMS

Cordex Pharma and Clinical Trials International sign license agreement for ATPotent

Prospect Therapeutics to develop GCS-100 for blood-borne cancers

Pharmexa issues consideration shares to Affitech shareholders under merger agreement

UCL/M initiates next step in phase I/II clinical trial of Targeted Genetics' AAV-RPE65 in LCA

GTx Inc. describes estrogen receptor-beta agonist for obesity treatment

Bayer Schering Pharma claims novel PAR-1 antagonists

Shanghai Hengrui discovers novel CETP inhibitors for the treatment of lipoprotein disorders

Takeda initiates phase III clinical trial of hypertension drug TAK-536 in Japan

Enzon initiates phase II trial of cancer drug PEG-SN38 in metastatic colon cancer

FDA approves Cambia for acute migraine with or without aura in adults

Wyeth extends research period under 2005 collaboration agreement with Trubion

Provectus initiates compassionate-use program in Australia for PV-10 in cancer

RegeneRx and U.S. military to test TB4 against exposure to chemical agents in the eye